AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12527962 — intervention group
Group type: COMPARATOR
Intervention: Normally menstruating women (NM) during follicular phase (FT)
Number of subjects: 15
Study 12527962 — intervention group
Group type: EXPERIMENTAL
Intervention: Normally menstruating women (NM) during luteal phase (LT)
Number of subjects: 15
Study 12527962 — intervention group
Group type: COMPARATOR
Intervention: Normally menstruating women (NM)
Number of subjects: 15
Study 12527962 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (OC) users
Number of subjects: 15
Study 11770139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Number of subjects: 10
Study 11770139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8750478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 0
Study 8750478 — intervention group
Group type: COMPARATOR
Intervention: Intravenous multidrug chemotherapy
Number of subjects: 0
Study 8325079 — intervention group
Group type: EXPERIMENTAL
Intervention: CB version (chronic bronchitis reference)
Number of subjects: 75
Study 8325079 — intervention group
Group type: COMPARATOR
Intervention: NCB version (no chronic bronchitis reference)
Number of subjects: 75
Study 8325079 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 3804883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 307
Study 3804883 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and Metronidazole
Number of subjects: 307
Study 29377317 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCE trial participation
Number of subjects: 22
Study 27565734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg/day of eicosapentaenoic acid (EPA), n = 53
Number of subjects: 107
Study 27565734 — intervention group
Group type: COMPARATOR
Intervention: No EPA, n = 54
Number of subjects: 107
Study 24953916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine moistened dressing (12 mL/100 cm2 of 0.25% bupivacaine solution)
Number of subjects: 150
Study 24953916 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing (moistened with normal saline)
Number of subjects: 150
Study 23297552 — intervention group
Group type: EXPERIMENTAL
Intervention: Series of formulas changed daily according to TCM syndrome
Number of subjects: 0
Study 23297552 — intervention group
Group type: COMPARATOR
Intervention: Only one formula
Number of subjects: 0
Study 20546250 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP with a 3-month healing period
Number of subjects: 31
Study 20546250 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP with a 4-month healing period
Number of subjects: 31
Study 20546250 — intervention group
Group type: COMPARATOR
Intervention: β‐TCP mixed with autologous bone with a 4-month healing period
Number of subjects: 31
Study 20546250 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP
Number of subjects: 31
Study 20546250 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGDF‐5
Number of subjects: 31
Study 18166463 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine
Number of subjects: 0
Study 18166463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15995113 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fixed‐bearing knee prosthesis
Number of subjects: 50
Study 15995113 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐flexion fixed‐bearing knee prosthesis
Number of subjects: 50
Study 14575403 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray
Number of subjects: 40
Study 14575403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14575403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 40
Study 10229464 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic percutaneous transluminal balloon angioplasty (PTA)
Number of subjects: 64
Study 10229464 — intervention group
Group type: COMPARATOR
Intervention: Control (observation without treatment)
Number of subjects: 64
Study 8970500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium, starting at 15 mg/kg of body weight, dosage increase every 3 to 4 days until response or serum level of 1.2 to 1.4 mEq/L
Number of subjects: 0
Study 8970500 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (divalproex), initiated at 20 mg/kg of body weight
Number of subjects: 0
Study 8970500 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine, starting at 200 mg once or twice daily with slow dosage escalation
Number of subjects: 0
Study 1713269 — intervention group
Group type: EXPERIMENTAL
Intervention: murine monoclonal anti‐CD4 (B‐F5) antibody (10 mg/day, 15 mg/day, 20 mg/day) for 10 consecutive days
Number of subjects: 10
Study 6711781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 69
Study 6711781 — intervention group
Group type: COMPARATOR
Intervention: Slow release morphine sulphate tablets (MST, 20 mg)
Number of subjects: 69
Study 30715637 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser treatment (wavelength 830 nm, 30 mW, power density 0.84 W/cm2)
Number of subjects: 0
Study 30715637 — intervention group
Group type: COMPARATOR
Intervention: LED treatment (wavelength 850 nm, 48 mW, power density 1.05 W/cm2)
Number of subjects: 0
Study 30715637 — intervention group
Group type: COMPARATOR
Intervention: Comparison of laser and LED therapies
Number of subjects: 0
Study 30715637 — intervention group
Group type: COMPARATOR
Intervention: Both therapies (laser and LED)
Number of subjects: 0
Study 29016823 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health check with CRF assessment
Number of subjects: 2201
Study 29016823 — intervention group
Group type: COMPARATOR
Intervention: Preventive health check without CRF assessment (Control)
Number of subjects: 2201
Study 27073929 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling using Evalyn Brush or Delphi Screener
Number of subjects: 800
Study 27073929 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a 2nd reminder letter
Number of subjects: 800
Study 27073929 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling subgroup
Number of subjects: 800
Study 23643048 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance, whole body long-axis rotational training
Number of subjects: 36
Study 23643048 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 36
Study 22158074 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HSP70 levels in pancreatic cancer patients (PC)
Number of subjects: 45
Study 20439348 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 37
Study 20439348 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 37
Study 17272969 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 mg treatment
Number of subjects: 17
Study 17272969 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 15665005 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based medication review by pharmacists (two home visits within two weeks and eight weeks of discharge)
Number of subjects: 872
Study 15665005 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 872
Study 15665005 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based medication review by pharmacists
Number of subjects: 872
Study 12177661 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 59
Study 12177661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 10453419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pancreatin
Number of subjects: 39
Study 10453419 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose pancreatin
Number of subjects: 39
Study 7885907 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination awareness
Number of subjects: 0
Study 7885907 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast awareness
Number of subjects: 0
Study 2358266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% MK‐417
Number of subjects: 27
Study 2358266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% MK‐927
Number of subjects: 27
Study 2358266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (common vehicle)
Number of subjects: 27
Study 402569 — intervention group
Group type: EXPERIMENTAL
Intervention: Segontin-Digoxin
Number of subjects: 30
Study 402569 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 30
Study 31680631 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 696
Study 31265450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1FOOT (1 day of 60-min 5 vs 5 football)
Number of subjects: 18
Study 31265450 — intervention group
Group type: EXPERIMENTAL
Intervention: 3FOOT (3 consecutive days of 60-min 5 vs 5 football)
Number of subjects: 18
Study 28040445 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine angiographic follow-up (AF) group
Number of subjects: 700
Study 28040445 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up alone (CF) group
Number of subjects: 700
Study 26586819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 75
Study 26586819 — intervention group
Group type: COMPARATOR
Intervention: Placebo conditioning
Number of subjects: 75
Study 26586819 — intervention group
Group type: COMPARATOR
Intervention: Sham mindfulness meditation
Number of subjects: 75
Study 26586819 — intervention group
Group type: COMPARATOR
Intervention: Book-listening control intervention
Number of subjects: 75
Study 24000709 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for community-acquired pneumonia with hypertension
Number of subjects: 60
Study 24000709 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with community-acquired pneumonia during treatment)
Number of subjects: 60
Study 22619907 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-mg of diclofenac sodium
Number of subjects: 46
Study 22619907 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 46
Study 20553075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (3,144)
Number of subjects: 3
Study 20553075 — intervention group
Group type: COMPARATOR
Intervention: Controls (10,661)
Number of subjects: 3
Study 17241410 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U botulinum toxin type A (BOTOX Cosmetic)
Number of subjects: 70
Study 17241410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17241410 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 70
Study 15159240 — intervention group
Group type: EXPERIMENTAL
Intervention: Food consumption during television viewing
Number of subjects: 2
Study 15159240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat content of foods consumed during television viewing
Number of subjects: 2
Study 15159240 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of food consumed during television viewing
Number of subjects: 2
Study 11304662 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 810
Study 11304662 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 810
Study 9629994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg o.d.) and digoxin (0.25 mg o.d.)
Number of subjects: 12
Study 9629994 — intervention group
Group type: COMPARATOR
Intervention: Placebo and digoxin (0.25 mg o.d.)
Number of subjects: 12
Study 7948814 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with combined gastric body and duodenal ulcers
Number of subjects: 127
Study 7948814 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with combined gastric angular and duodenal ulcers
Number of subjects: 127
Study 7948814 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with combined gastric antral and duodenal ulcers
Number of subjects: 127
Study 7948814 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 127
Study 3063488 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 25
Study 3063488 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 25
Study 3063488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28797312 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived difficulties in performing IADLs
Number of subjects: 2802
Study 28797312 — intervention group
Group type: COMPARATOR
Intervention: Cognitive tests of memory, reasoning, and speed of processing
Number of subjects: 2802
Study 28929343 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (8% carbohydrate-electrolyte drink, 20 g h-1)
Number of subjects: 22
Study 28929343 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin (8% carbohydrate-electrolyte drink, 20 g h-1)
Number of subjects: 22
Study 28929343 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (both isomaltulose and maltodextrin)
Number of subjects: 22
Study 28929343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both carbohydrates (isomaltulose and maltodextrin)
Number of subjects: 22
Study 28929343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carbohydrate-energy-free)
Number of subjects: 22
Study 25846721 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300
Number of subjects: 807
Study 25846721 — intervention group
Group type: COMPARATOR
Intervention: Gla-100
Number of subjects: 807
Study 23596158 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 253
Study 23596158 — intervention group
Group type: COMPARATOR
Intervention: Low Protein (LP) diet
Number of subjects: 253
Study 23596158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet
Number of subjects: 253
Study 23596158 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 253
Study 21912346 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle fatigue (IMF) trial
Number of subjects: 8
Study 21912346 — intervention group
Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 8
Study 18199149 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush with triclosan dentifrice
Number of subjects: 128
Study 18199149 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush and standard dentifrice
Number of subjects: 128
Study 18199149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study 16775595 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 20
Study 12809659 — intervention group
Group type: EXPERIMENTAL
Intervention: Knifelight group
Number of subjects: 82
Study 12809659 — intervention group
Group type: COMPARATOR
Intervention: Open operation group
Number of subjects: 82
Study 10807453 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty in diabetics (n = 81)
Number of subjects: 1138
Study 10807453 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty in nondiabetics (n = 391)
Number of subjects: 1138
Study 10807453 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty in nondiabetics versus accelerated alteplase
Number of subjects: 1138
Study 10807453 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty in diabetics versus accelerated alteplase
Number of subjects: 1138
Study 8741719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 36
Study 8741719 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 36
Study 8741719 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 36
Study 1449044 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r‐hGH) (0.1 IU/kg sc twice daily)
Number of subjects: 20
Study 1449044 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 2933055 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA combined with mechlorethamine (group B)
Number of subjects: 40
Study 2933055 — intervention group
Group type: COMPARATOR
Intervention: Mechlorethamine applied topically (group A)
Number of subjects: 40
Study 30387163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU)
Number of subjects: 150
Study 30387163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 29413685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m2 and Gemcitabine 1000 mg/m2 with Panitumumab (arm A)
Number of subjects: 90
Study 29413685 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 25 mg/m2 and Gemcitabine 1000 mg/m2 without Panitumumab (arm B)
Number of subjects: 90
Study 26789348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 32
Study 26789348 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-Modified Diet (CMD)
Number of subjects: 32
Study 23937797 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency BMBPC
Number of subjects: 23
Study 23937797 — intervention group
Group type: COMPARATOR
Intervention: Medium frequency BMBPC
Number of subjects: 23
Study 21289016 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (group B)
Number of subjects: 231
Study 21289016 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% hydrogen peroxide (group C)
Number of subjects: 231
Study 21289016 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A) with no alteration in dental colour
Number of subjects: 231
Study 19231484 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified capture rate (MCR) group with initial capture rate at 0.5 fps, modified to 2 fps after passing pylorus.
Number of subjects: 50
Study 19231484 — intervention group
Group type: COMPARATOR
Intervention: Control group with a constant capture rate of 2 fps.
Number of subjects: 50
Study 19231484 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified capture rate (MCR) group.
Number of subjects: 50
Study 19231484 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 50
Study 17487649 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/MPA 0.625/2.5 mg/day
Number of subjects: 1028
Study 17487649 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/MPA 0.45/1.5 mg/day
Number of subjects: 1028
Study 17487649 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/MPA 0.3/1.5 mg/day
Number of subjects: 1028
Study 16205431 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill training for 12 weeks
Number of subjects: 98
Study 16205431 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 98
Study 11837705 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANNs) for predictive PK and PD modeling
Number of subjects: 0
Study 11837705 — intervention group
Group type: COMPARATOR
Intervention: Naive averaging (NA)
Number of subjects: 0
Study 11837705 — intervention group
Group type: COMPARATOR
Intervention: Randomly generated numbers (RN)
Number of subjects: 0
Study 11072423 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 608
Study 11072423 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 608
Study 11072423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 7782257 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 32
Study 7782257 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 32
Study 1910887 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative learning model
Number of subjects: 0
Study 1910887 — intervention group
Group type: COMPARATOR
Intervention: Traditional curriculum
Number of subjects: 0
Study 7033014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopenthiazide (Navidrex)
Number of subjects: 648
Study 7033014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release oxprenolol (Slow‐Trasicor)
Number of subjects: 648
Study 7033014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of cyclopenthiazide and oxprenolol (Trasidrex)
Number of subjects: 648
Study 7033014 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous treatment discontinued)
Number of subjects: 648
Study 31289019 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 31289019 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1800
Study 31289019 — intervention group
Group type: EXPERIMENTAL
Intervention: Major infections
Number of subjects: 1800
Study 30447975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene-enriched ice cream
Number of subjects: 0
Study 30447975 — intervention group
Group type: COMPARATOR
Intervention: Control ice cream
Number of subjects: 0
Study 28712000 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 10 gm/day
Number of subjects: 1619
Study 28712000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1619
Study 26405291 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP‐RSI (asthma educational programme based on a repeated short intervention)
Number of subjects: 230
Study 26405291 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP‐RSI
Number of subjects: 230
Study 26405291 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice group
Number of subjects: 230
Study 26405291 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold standard group (standard educational programme)
Number of subjects: 230
Study 25607552 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole topical solution, 10%
Number of subjects: 112
Study 25607552 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 112
Study 22731246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg/0.1 mL)
Number of subjects: 27
Study 22731246 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 27
Study 18997832 — intervention group
Group type: EXPERIMENTAL
Intervention: ATL-104 (50, 100 or 150 mg)
Number of subjects: 63